Literature DB >> 32061575

Early kinetic profiles of troponin I and T measured by high-sensitivity assays in patients with myocardial infarction.

John W Pickering1, Joanna M Young2, Peter M George3, Christopher J Pemberton4, Antony Watson5, Sally J Aldous5, Toby Verryt5, Richard W Troughton2, A Mark Richards6, Fred S Apple7, Martin P Than5.   

Abstract

The early concentration kinetic profiles of cardiac troponin in patients with non-ST-elevated myocardial infarction (NSTEMI) measured by high-sensitivity cardiac troponin I (hs-cTnI) and T (hs-cTnT) assays have not been described. In intermediate-to-high-risk of NSTEMI patients we measured serial cTn concentrations on ED arrival, at 1, 2, 3, 6-12, 24 and 48-hours with hs-cTnI and hs-cTnT assays. Log-normal curves were fitted to concentrations from time from symptom onset, and the time to rule-out decision thresholds estimated (hs-cTnI: 2 ng/L and 5 ng/L; hs-cTnT: 5 ng/L). Among 164 patients there were 58 NSTEMI. The hs-cTnI to hs-cTnT ratio increased linearly over the first 6-12 h following symptom onset. The estimated times from symptom onset to the 2 ng/L and 5 ng/L thresholds for hs-cTnI were 1.8 (0.1-3.1) and 1.9 (1.1-3.5) hours, and to the 5 ng/L threshold for hs-cTnT 1.9 (1.1-3.8) hours. The estimated time to exceed 5 ng/L was ≥3 hours in 32.6% (95%CI: 20.0% to 48.1%) cases for hs-cTnI and 33.3% (19.6% to 50.0%) for hs-cTnT. cTnI concentrations increased at a much more rapid rate than cTnT concentrations in patients with NSTEMI. Concentrations of a high proportion of patients took longer than 3 hours from symptom onset to exceed the 5 ng/L rule-out decision threshold.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute myocardial infarction; Emergency department; Emergency room; High-sensitivity cardiac troponin; Kinetics

Year:  2020        PMID: 32061575     DOI: 10.1016/j.cca.2020.02.009

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  4 in total

1.  Evaluation of Dual Marker Approach Using Heart-Type Fatty Acid Binding Protein and High Sensitivity Troponin-I as an Alternative to Serial Sampling for Diagnosis of Acute Myocardial Infarction.

Authors:  Manish Raj Kulshrestha; Apurva Raj; Vandana Tiwari; Subrat Chandra; Bhuwan Chandra Tiwari; Ashish Jha
Journal:  EJIFCC       Date:  2022-04-11

2.  The Diagnostic Value of Serum GDF15 and hs-CTnT in Elderly Patients with Acute Myocardial Infarction.

Authors:  Yejun He; Hui Wang; Zhihua Fang
Journal:  Comput Intell Neurosci       Date:  2022-05-20

3.  Reducing Patient Risk and Enhancing Care Through the Development and Implementation of a New Chest Pain Pathway, Expedited by and for the COVID-19 Era.

Authors:  Martin P Than; John W Pickering; Philip Adamson; Thomas Clendon; Christopher M Florkowski; John Lainchbury; Jacques Loubser; Alison Nankivel; Sally J Aldous
Journal:  EJIFCC       Date:  2021-02-28

4.  Kinetics, Moderators and Reference Limits of Exercise-Induced Elevation of Cardiac Troponin T in Athletes: A Systematic Review and Meta-Analysis.

Authors:  Feifei Li; Will G Hopkins; Xuejing Wang; Julien S Baker; Jinlei Nie; Junqiang Qiu; Binh Quach; Kun Wang; Longyan Yi
Journal:  Front Physiol       Date:  2021-03-26       Impact factor: 4.566

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.